{"id":"biosimilar-insulin-glargine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog designed to provide steady, long-acting glycemic control over approximately 24 hours. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose uptake and storage while suppressing hepatic glucose production. As a biosimilar, it is a biologically equivalent version of the reference insulin glargine product, manufactured through recombinant DNA technology.","oneSentence":"Biosimilar insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:01.552Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06717191","phase":"PHASE4","title":"Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-06-09","conditions":"Type 1 Diabetes","enrollment":296},{"nctId":"NCT06674135","phase":"PHASE4","title":"Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-06-01","conditions":"Type I Diabetes","enrollment":202},{"nctId":"NCT06624943","phase":"PHASE4","title":"Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-03-14","conditions":"Type 1 Diabetes (T1D)","enrollment":260},{"nctId":"NCT02967224","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":705},{"nctId":"NCT02967211","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12-21","conditions":"Diabetes Mellitus, Type 2","enrollment":609},{"nctId":"NCT02922179","phase":"","title":"Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics","status":"COMPLETED","sponsor":"Biologics & Biosimilars Collective Intelligence Consortium","startDate":"2011-01-01","conditions":"Diabetes","enrollment":103951},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT04591457","phase":"PHASE2","title":"The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2020-10","conditions":"Diabetes Mellitus","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Basaglar"],"phase":"marketed","status":"active","brandName":"biosimilar insulin glargine","genericName":"biosimilar insulin glargine","companyName":"Life for a Child Program, Diabetes Australia","companyId":"life-for-a-child-program-diabetes-australia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biosimilar insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}